

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL	
OMB Number:	3235-0104
Estimated average burden hours per response:	0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>KPCB PBD Associates, LLC</u> (Last) (First) (Middle) C/O KLEINER PERKINS CAUFIELD & BYERS 2750 SAND HILL ROAD (Street) MENLO PARK CA 94025 (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) 07/13/2023	3. Issuer Name and Ticker or Trading Symbol <u>Sagimet Biosciences Inc. [SGMT]</u>	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below)	5. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person <input checked="" type="checkbox"/> Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	38,763	I	See footnote ⁽¹⁾

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Series A Preferred Stock	(2)	(2)	Common Stock	6,781	(2)	I	See footnote ⁽¹⁾
Series B Preferred Stock	(2)	(2)	Common Stock	6,208	(2)	I	See footnote ⁽¹⁾
Series B-1 Preferred Stock	(2)	(2)	Common Stock	108,163	(2)	I	See footnote ⁽¹⁾
Series C Preferred Stock	(2)	(2)	Common Stock	108,163	(2)	I	See footnote ⁽¹⁾
Series D Preferred Stock	(2)	(2)	Common Stock	76,796	(2)	I	See footnote ⁽¹⁾
Series E Preferred Stock	(2)	(2)	Common Stock	1,297,549	(2)	I	See footnote ⁽¹⁾
Series F Preferred Stock	(2)	(2)	Common Stock	257,052	(2)	I	See footnote ⁽¹⁾

1. Name and Address of Reporting Person* <u>KPCB PBD Associates, LLC</u> (Last) (First) (Middle) C/O KLEINER PERKINS CAUFIELD & BYERS 2750 SAND HILL ROAD (Street) MENLO PARK CA 94025 (City) (State) (Zip)
--

1. Name and Address of Reporting Person*
--

**KPCB PANDEMIC & BIO DEFENSE
FUND LLC**

(Last) (First) (Middle)
**C/O KLEINER PERKINS CAUFIELD & BYERS
2750 SAND HILL ROAD**

(Street)
MENLO PARK CA 94025

(City) (State) (Zip)

Explanation of Responses:

1. Represents shares held directly by KPCB Pandemic and Bio Defense Fund, LLC ("KPCB PBD"). The managing member of KPCB PBD is KPCB PBD Associates, LLC ("KPCB PBD Associates"). All securities are held for convenience in the name of "KPCB Holdings, Inc., as nominee". KPCB PBD Associates disclaims Section 16 beneficial ownership of the shares reported herein except to the extent of its pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of any of the reported shares for purposes of Section 16 or any other purpose.

2. Each share of Series A Preferred Stock, Series B Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock and Series F Preferred Stock (collectively, the "Preferred Stock") is convertible into Common Stock on a 79.4784-to-one basis (on an adjusted basis, after giving effect to the reverse stock split of the Common Stock effected by the Issuer on July 7, 2023) at the option of the holder, and will convert automatically upon closing of the Issuer's initial public offering into the number of shares shown in column 3. The Preferred Stock has no expiration date.

KPCB PBD Associates,
LLC, By: /s/ Susan Biglieri, CFO 07/13/2023

KPCB Pandemic and Bio
Defense Fund, LLC, By:
KPCB PBD Associates,
LLC, its managing
member, By: /s/ Susan
Biglieri, CFO 07/13/2023

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.